Is nevirapine dose-escalation appropriate in young, African, HIV-infected children?

AIDS

Volumn 27, Issue 13, 2013, Pages 2111-2115

  Fillekes, Quirine ^a   Mulenga, Veronica ^b   Kabamba, Desiré ^b   Kankasa, Chipepo ^b   Thomason, Margaret J ^c   Cook, Adrian ^c   Chintu, Chifumbe ^b   Gibb, Diana M ^c   Walker, A Sarah ^c   Burger, David M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY TEACHING HOSPITAL   (Zambia)

^c MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

Africa; Children; Dose escalation; HIV; Nevirapine; Pharmacokinetics

Indexed keywords

LAMIVIR S; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; TRIOMUNE BABY; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CHILD CARE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; GROUPS BY AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NEGRO; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VIRUS LOAD; ZAMBIA;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; EXANTHEMA; FEMALE; HIV; HIV INFECTIONS; HUMANS; INFANT; MALE; MOLECULAR SEQUENCE DATA; NEVIRAPINE; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; VIRAL LOAD; ZAMBIA;

EID: 84884499380     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283620811     Document Type: Article

References (10)

1. World Health Organisation. Antiretroviral therapy of HIV infection in infants and children: towards universal access. Recommendations for a public health approach: 2010 revision. Geneva: World Health Organisation; 2010. http://www.who. int/hiv/pub/paediatric/infants2010/en/index.html. [Accessed 15 December 2011].
2. Barreiro P, Soriano V, Casas E, Estrada V, Tellez MJ, Hoetelmans R, et al. Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. AIDS 2000; 14: 2153-2157.
3. Vries-Sluijs TE, Dieleman JP, Arts D, Huitema AD, Beijnen JH, Schutten M, et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet 2003; 42:599-605.
4. Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15:1261-1268.
5. Luzuriaga K, Bryson Y, McSherry G, Robinson J, Stechenberg B, Scott G, et al. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis 1996; 174:713-721.
6. Ellis JC, L'Homme RFA, Ewings FM, Mulenga V, Bell F, Chileshe R, et al. Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia. Antivir Ther 2007; 12:253-260.
7. Mulenga V, Cook A, Walker AS, Kabamba D, Chijoka C, Ferrier A, et al. Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination 'baby pills' in Zambia: a randomized controlled trial. Clin Infect Dis 2010; 51:1081-1089.
8. Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, Kamthunzi P, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 2012; 366: 2380-2389.
9. Hollanders RMW, van Ewijk-Beneken Kolmer EWJ, Burger DM, Wuis EW, Koopmans PP, Hekster YA. Determination of nevirapine, an HIV-1 nonnucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. J Chromat B Biomed Sci Appl 2000; 744:65-71.
10. Nahirya-Ntege P, Cook A, Vhembo T, Opilo W, Namuddu R, Katuramu R, et al. Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa. PLoS One 2012; 7:e36186.